OriGene to add antibody expertise with $16M SDIX deal

04/9/2013 | GenomeWeb Daily News (free registration)

SDIX will sell its life science assets to OriGene Technologies for $16 million. The deal is expected to be finalized this quarter. SDIX's knowledge in antibody development and production "will complement OriGene's existing high-throughput monoclonal antibody capacity to develop the highest quality antibodies," OriGene Chairman and CEO Wei-Wu He said.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA